Maccabi Healthcare Services, Tel-Aviv, Israel.
Leuk Res. 2012 Mar;36(3):327-30. doi: 10.1016/j.leukres.2011.11.008. Epub 2011 Dec 3.
We have utilized the computerized data of a nationwide health plan to elucidate several epidemiologic aspects and risk factor of myelodysplastic syndromes (MDS) in Israel. The annual incidence rate (IR) of reported MDS was of 3.32 per 100,000. Among anemic patients aged 40+, the risk of reported MDS was 56.7 per 100,000. Only 44% of the reported MDS cases had an indication of bone marrow examination. In a multivariable model, older age, hemoglobin level <9 g/dl, white blood cell count of less than 3500/mm(3), and platelet count of less than 100×10(9)/L were associated with a significantly higher risk of MDS. The mean lag period from the first demonstration of anemia to the final diagnosis of MDS was 3.5 years. Our study results could be helpful for improving the detection of patients with high MDS risk, therapeutic decision-making, and designing interventional trials in the future.
我们利用全国健康计划的计算机化数据阐明了以色列骨髓增生异常综合征（MDS）的几个流行病学方面和危险因素。报告 MDS 的年发病率（IR）为每 10 万人 3.32 例。在 40 岁以上贫血患者中，报告 MDS 的风险为每 100,000 人 56.7 例。仅有 44%的报告 MDS 病例有骨髓检查指征。在多变量模型中，年龄较大、血红蛋白水平<9 g/dl、白细胞计数<3500/mm(3)和血小板计数<100×10(9)/L 与 MDS 的风险显著增加相关。从首次贫血表现到 MDS 最终诊断的平均滞后时间为 3.5 年。我们的研究结果有助于提高对高 MDS 风险患者的检测、治疗决策以及未来设计干预试验的能力。
Zotero 插件